SEED Discloses Novel Molecular Glue IND Candidate at “TPD Think Tank” Symposium.
SEED Achieved 3rd Milestone with Lilly R&D Collaboration in March 2024.
SEED Therapeutics’ Mission
To break through the scientific barriers to discovering Molecular Glues for effective therapy and cures for the world’s most debilitating diseases and disorders.
Collaborating with an unparalleled team of world-leading experts in the Ubiquitin Proteasome System and the field of Targeted Protein Degradation. SEED Therapeutics is advancing its groundbreaking Molecular Glues discovery platform for the treatment of multiple indications, including cancer, neurodegradation, and infectious diseases.
DRUG DISCOVERY
SEED Therapeutics: A focus on Molecular Glues
SEED Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use Molecular Glues to attack protein targets previously believed to be ”undruggable.”
PIPELINE
THE TEAM
Click below to learn more about SEED Therapeutics’ leadership
NEWSROOM
SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology
March 6, 2024: Nature Biotechnology, a transformative journal covering the science and business of biotechnology, published a review article on the significant challenges facing molecular glue companies seeking to remove undruggable disease-causing proteins,...
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium NEW YORK, October 26, 2023 – SEED Therapeutics Inc. (“SEED”), a...
SEED Theraputics, a BeyondSpring Subsiniary, Appoints Mr. Ko-Yung Tung to the Board of Directors
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member, Former World Bank General Counsel, and Lecturer at Harvard and Yale Law...
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
info@seedtherapeutics.cominfo@seedtherapeutics.com PRESS RELEASES Seed Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors New York, NY – June 20, 2023 – SEED Therapeutics (the “Company”), a BeyondSpring (NASDAQ: BYSI) subsidiary...
Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania
info@seedtherapeutics.cominfo@seedtherapeutics.com PRESS RELEASESSeed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania. King of Prussia, PA – July 01, 2022 –...
Events
“Targeted Protein Degradation Think Tank” Symposium
PARTNERS
CAREERS
